Victoria Socha

DocwireNews

Researchers at Mount Sinai Hospital, New York, New York, conducted a study to examine short-term outcomes and peri- and post-transplant complications in <a href="https://www.docwirenews.com/nephtimes/nephtimes-conferences/american-transplant-congress-2021/outcomes-in-living-kidney-donors-with-prior-covid-19/">patients with prior COVID-19</a> who subsequently underwent kidney transplantation. A. Santeusanio reported results of the single-center, retrospective cohort study during a virtual session at the 2021 American Transplant Congress in a presentation titled Kidney Transplantation in Patients with Prior Coronavirus Disease 2019 (COVID-19).The study included all recipients of isolated living- or deceased-donor kidney transplants at the center between April 1, 2020, and October 1, 2020. Patients with prior COVID-19 confirmed on polymerase chain reaction (PCR) were deemed candidates for kidney transplantation if they were a minimum of 4 weeks post-infection, had resolution of symptoms, and had one negative nasopharyngeal PCR swab specimen.At the time of transplant, recipients received standard doses of induction and maintenance immunosuppression, including anti-thymocyte globulin, tacrolimus, mycophenolate, and tapering corticosteroids. Patients were followed from the date of the transplant until the conclusion of the study (November 1, 2020). The researchers compared short-term patient and allograft outcomes between recipients with prior COVID-19 and COVID-19 na&iuml;ve controls who received a kidney transplant during the study period.During the study period, 81 patients received isolated kidney transplants at the center. Of those, 13 (16.0%) had recovered from prior COVID-19 infection. Median time between diagnosis of COVID-19 and transplantation was 71 days. Ten patients who were tested had evidence of significant antibody titers to the SARS-CoV-2 spike protein. Among the group with prior COVID-19, 69.2% had mild disease; three patients required hospital admission and supplemental oxygen and one required mechanical ventilation. The two groups were similar in baseline characteristics, with the exception of a greater proportion of Hispanic/Latino patients in the group with prior COVID-19 than in the control group (53.8% vs 17.6%; P&lt;.01).At the conclusion of the study, following a median of 36 months of follow-up, patient and allograft survival were similar between the two groups (92.3%/92.3% vs 100%/98.5%), and mean baseline serum creatinine was 1.5 mg/dL in both groups. One patient in the prior COVID-19 group (mild) died due to a pulmonary embolism within 1 month of transplantation; there were no significant differences overall in the rate of thromboembolism between the groups (7.7% vs 4.4%; P=.61).The two groups were similar in index hospital length of stay and 30-day readmission rate; patients in the prior COVID-19 group had a higher incidence of delayed extubation post-transplant (15.4% vs 1.5%; P=.02). There were no cases of COVID-19 reinfection or biopsy proven allograft rejection among patients in the prior COVID-19 group.In conclusion, the authors said, &ldquo;In our preliminary experience, patients with prior COVID-19 infection appeared to have similar short-term outcomes when compared with COVID-19 na&iuml;ve patients. We did observe a potential signal for increased peri-operative respiratory complications in patients with prior CVOID-19, which may warrant additional monitoring and further study in multi-center cohorts.&rdquo;Source: Santeusanio A, Bhansali A, Rana S, et al. Kidney transplantation in patients with prior coronavirus disease 2019 (COVID-19). Abstract of a presentation at the virtual American Transplant Congress (Abstract LB 44), June 5, 2021.

Dr. Sadie Dobrozsi, Evolent

Rob Dillard

Genomics Tailors Breast Cancer Care, Cuts Unneeded Chemo

Genetics & Breast Cancer

Andrew Moreno

Extending Anticoagulation is Reasonable in Children with VTE, Data Suggest

Katie Kosko

DESTINY-Breast06: T-DXd Beats Chemo in HER2-Low HR+ mBC

Breast Cancer News

Latest News

Short-Term Outcomes in Transplant Recipients with Prior COVID-19

American Transplant Congress 2021

Researchers at Mount Sinai Hospital, New York, New York, conducted a study to examine short-term outcomes and peri- and post-transplant complications in patients with prior ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe